Price
Target price
€2.55
€2.55
-2.260%
-0.06
-2.260%
-
16.03.26 / Tradegate
WKN: 520394 / Name: B.R.A.I.N. Biotechnology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock B.R.A.I.N. Biotechnology Research and Information Network AG is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for B.R.A.I.N. Biotechnology
sharewise wants to provide you with the best news and tools for B.R.A.I.N. Biotechnology, so we directly link to the best financial data sources.
Financials
News
EQS-News: Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
EQS-News: Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control
EQS-News: FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control